Search
Onconetix Inc
ONCOAdd to Watchlist
0.956USD
-0.124-11.53%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
298.24KMarket Cap
0.00P/E TTM
More Details of Onconetix Inc Company
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Onconetix Inc Info
Ticker SymbolONCO
Company nameOnconetix Inc
IPO dateFeb 18, 2022
CEOFedasz (Karina M)
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 18
Address201 E. Fifth Street
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45202
Phone15136204101
Websitehttps://www.onconetix.com/
Ticker SymbolONCO
IPO dateFeb 18, 2022
CEOFedasz (Karina M)
Company Executives of Onconetix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
132.00
-6.06%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
132.00
-6.06%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
FAQs
Who are the top five shareholders of Onconetix Inc?
The top five shareholders of Onconetix Inc are: Mr. Simon Tarsh
How many institutions hold shares of Onconetix Inc (ONCO)?
As of 2026Q1, 29 institutions hold shares of Onconetix Inc, with a combined market value of approximately 26.70K, accounting for 3.85% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2185.00.